Literature DB >> 17045188

Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials.

Kiran K Khush1, David D Waters.   

Abstract

BACKGROUND: Statin therapy has been shown to effectively lower low-density lipoprotein cholesterol levels and reduce cardiovascular events. Statins also appear to exert other favorable effects, including anti-inflammatory actions and improvement in endothelial function. Statin therapy may therefore yield important clinical benefits in patients with heart failure-a physiologic state characterized by systemic inflammation and endothelial dysfunction. METHODS AND
RESULTS: This review summarizes basic and clinical investigations regarding the role of statin therapy in heart failure, focusing on potential mechanisms and preliminary clinical data. There is now extensive evidence suggesting that statins improve endothelial function, inhibit neurohormonal activation, restore autonomic balance, reduce inflammation, and prevent ventricular remodeling. Retrospective and small-scale prospective studies suggest that statins prevent the development of heart failure and reduce mortality in patients with established HF.
CONCLUSION: Preliminary evidence supports a role for statins in improving surrogate markers and clinical outcomes in ischemic and nonischemic heart failure. Large-scale randomized clinical trials are needed to definitively address this important topic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045188     DOI: 10.1016/j.cardfail.2006.05.003

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  9 in total

Review 1.  Potential role of statins in the treatment of heart failure.

Authors:  Stuart D Katz
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

Review 2.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

Authors:  J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

3.  Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial.

Authors:  Tamara B Horwich; Holly R Middlekauff; W Robb Maclellan; Gregg C Fonarow
Journal:  J Card Fail       Date:  2011-09-03       Impact factor: 5.712

4.  Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells.

Authors:  Patrick A Paez; Motunrayo Kolawole; Marcela T Taruselli; Siddarth Ajith; Jordan M Dailey; Sydney A Kee; Tamara T Haque; Brian O Barnstein; Jamie Josephine Avila McLeod; Heather L Caslin; Kasalina N Kiwanuka; Yoshihiro Fukuoka; Quang T Le; Lawrence B Schwartz; David B Straus; David A Gewirtz; Rebecca K Martin; John J Ryan
Journal:  J Pharmacol Exp Ther       Date:  2020-05-20       Impact factor: 4.030

5.  Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production.

Authors:  Marcela T Taruselli; Elizabeth Motunrayo Kolawole; Amina Abdul Qayum; Tamara T Haque; Heather L Caslin; Daniel Abebayehu; Sydney A Kee; Jordan M Dailey; Kaitlyn G Jackson; Jason R Burchett; Andrew J Spence; Neha Pondicherry; Brian O Barnstein; Gregorio Gomez; David B Straus; John J Ryan
Journal:  Cell Immunol       Date:  2021-11-24       Impact factor: 4.868

6.  Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells.

Authors:  Benjaporn Buranrat; Wanwisa Suwannaloet; Jarinyaporn Naowaboot
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

7.  Potential autonomic nervous system effects of statins in heart failure.

Authors:  Tamara B Horwich; Holly R Middlekauff
Journal:  Heart Fail Clin       Date:  2008-04       Impact factor: 3.179

Review 8.  Update on statin-mediated anti-inflammatory activities in atherosclerosis.

Authors:  Fabrizio Montecucco; François Mach
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

9.  Labeling galectin-3 for the assessment of myocardial infarction in rats.

Authors:  Teresa Arias; Artiom Petrov; Jiqiu Chen; Hans de Haas; Carlos Pérez-Medina; Gustav J Strijkers; Roger J Hajjar; Zahi A Fayad; Valentín Fuster; Jagat Narula
Journal:  EJNMMI Res       Date:  2014-12-14       Impact factor: 3.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.